1 results
Approved WMOCompleted
The primary objective of this study is to assess the efficacy of pridopidine 67.5 to 112.5 mg twice daily (bid) on motor impairment in patients with HD after 26 weeks of treatment using the Unified Huntington*s Disease Rating Scale (UHDRS) Total…